TITLE

Use of pure opioid antagonists for management of opioid-induced pruritus

AUTHOR(S)
Miller, Jamie L.; Hagemann, Tracy M.
PUB. DATE
August 2011
SOURCE
American Journal of Health-System Pharmacy;8/1/2011, Vol. 68 Issue 15, p1419
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. Published reports on placebo-controlled clinical trials and other studies investigating the use of pure opioid antagonists for the prevention and treatment of opioid-induced pruritus (OIP) were evaluated. Summary. OIP is a common adverse effect of therapeutic use of opioid medications that can have a major impact on patients' comfort, quality of life, and willingness to continue opioid therapy. A literature search identified more than a dozen published reports on the use of pure opioid antagonists (naloxone, naltrexone, methylnaltrexone) for the management of OIP in pediatric and adult patients. Of the studies included in this review, most investigated the effects of naloxone administered by various parenteral routes for the prevention of OIP. Some of those studies indicated a significant reduction in the frequency or severity of pruritus with use of naloxone (a low-dose, continuous i.v. infusion of naloxone appeared to be the most effective treatment). A significant diminution of analgesia requiring increased cumulative doses of morphine was also observed in some studies. A number of studies evaluating the use of orally administered naltrexone for the management of OIP yielded generally less favorable results. Evidence from one small study suggested a potential role for orally administered methylnaltrexone in the prevention of OIP. Conclusion. Based on the existing data, a low-dose, continuous i.v. infusion of naloxone has the largest body of evidence supporting its use for prevention of OIP in adult and pediatric patients.
ACCESSION #
63627514

 

Related Articles

  • Opioid-Induced Constipation Part 2: Newer Therapies #295. Badke, Andrew; Rosielle, Drew A. // Journal of Palliative Medicine;Oct2015, Vol. 18 Issue 10, p893 

    The article presents various facts related to the opioid-induced constipation (OIC) and its treatment. It focuses on the use of agents for refractory OIC, which depicts persistent and distressing symptoms despite exposure to effective doses of stimulant and osmotic laxatives. It states that...

  • Opioid-induced constipation in children's palliative care. Stewart, Grace; McNeilly, Patricia // Nursing Children & Young People;Oct2011, Vol. 23 Issue 8, p31 

    Accurate assessment and management of children's symptoms at the end of life is a vital part of the children's nurse role. Most children experience pain at this stage and opioids are the drug of choice in those requiring a palliative approach to care. Opioids are, however, not without side...

  • Nonprescription naloxone: Pros and cons. Bastianelli, Karen M. S.; Orr, Katherine Kelly // Journal of the American Pharmacists Association: JAPhA;Jul/Aug2014, Vol. 54 Issue 4, p328 

    The article discusses the pros and cons of making naloxone an over-the-counter (OTC) drug to reduce the incidence of overdose fatalities. Topics include the role of opioid analgesics in drug overdose deaths, safety and ethical concerns on the expanded use of naloxone, and steps that should be...

  • Oral methylnaltrexone for opioid-induced constipation. Yuan, C S; Foss, J F // JAMA: Journal of the American Medical Association;9/20/2000, Vol. 284 Issue 11, p1383 

    No abstract available.

  • Easy-to-Use Overdose Antidote Earns Fast-Track Approval. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;4/23/2014, Vol. 311 Issue 16, p1600 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the Evzio, an opioid overdose antidote for outpatients that contain a single dose of naloxone. Topics discussed include the use of naloxone in emergency departments to reverse the effects of an illicit or prescription...

  • Nalmefene for Reduced-Risk Drinking: it is not Only Fancy Term For Harm Reduction. Evren, Cuneyt // Dusunen Adam: Journal of Psychiatry & Neurological Sciences;Dec2014, Vol. 27 Issue 4, p275 

    The author discusses the use of nalmefene in the treatment of alcohol use disorders (AUDs). Topics covered include the prevalence of AUDs worldwide, the efficacy of the drug in reducing heavy drinking and craving, and the emergence of reduced-risk-drinking as a public health approach known as...

  • CORRIGENDUM.  // Alcohol & Alcoholism;Nov/Dec2013, Vol. 48 Issue 6, p746 

    A correction to the article "Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies" that was published in a 2013 issue is presented.

  • Opioid-Induced Bowel Dysfunction: Pathophysiology and Potential New Therapies. Kurz, Andrea; Sessler, Daniel I. // Drugs;2003, Vol. 63 Issue 7, p649 

    Opioid treatment for postoperative or chronic pain is frequently associated with adverse effects, the most common being dose-limiting and debilitating bowel dysfunction. Postoperative ileus, although attributable to surgical procedures, is often exacerbated by opioid use during and following...

  • Naloxegol increases frequency of bowel movements and combats inadequate response to laxatives. Holzer, Peter // Evidence Based Medicine;Feb2015, Vol. 20 Issue 1, p5 

    In this article, the author comments on a study conducted by researcher W.D. Chey and colleagues on the impact of naloxegol in preventing constipation induced due to therapeutic action of opoid analgesics and its comparison with laxatives. Topics discussed include enhanced response of naloxegol...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics